EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
Traws Pharma, Inc.
TRAW

TRAW Traws Pharma, Inc.

Traws Pharma, Inc. · NASDAQ
Market Closed
0.49
▼ ⁦-8.50%⁩ (-0.05)
Market Cap$7.5M
Beta1.60
52w Low52w High
0.433.27
Last Week
⁦-7.81%⁩
Last Month
⁦-14.19%⁩
Last 3 Months
⁦-35.17%⁩
Last Year
⁦-74.35%⁩
EL7 Factor Analysis
How we score this
Overall23
Poor — bottom quartile of the marketContrarianF 4/8Better than 23% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
53
0.1x▲17.6xAround median
▸
Growth
96
—7.1%Top tier
▸
Quality
100
—4.5%Top tier
▸
Safety
22
—2.6xBottom tier
▸
Capital Return
55
—2.15%Around median
▸
Momentum
4
-70.1%▼2.3%Bottom tier
▸
Sentiment
23
1▼3Bottom tier

Frequently Asked Questions

What is Traws Pharma, Inc. stock?▼

Traws Pharma, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

How can I invest in Traws Pharma, Inc.?▼

You can buy Traws Pharma, Inc. shares through a licensed brokerage. Research the company's financials before investing.

What are the key metrics for evaluating Traws Pharma, Inc.?▼

Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

Does Traws Pharma, Inc. pay dividends?▼

Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

What are the risks of investing in Traws Pharma, Inc.?▼

Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.

Fair Value
Low confidenceCurrent price$0.49
Analyst target · 1 analysts
$1.00
—
Range ⁦$1.00–$1.00⁩
vs
DCF (estimate)
N/A (negative FCF)

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener

AI analysis from the earnings call, financials and news

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 1 analysts setting price target
$1.00
⁦+104.1%⁩
Current Price $0.49·Median $1.00
Low
$1.00
High
$1.00
Street summary

Traws Pharma (TRAW) Price Target Analysis

Traws Pharma stock shows complete stability in its price target at $1.00 over the past thirty days, representing a price premium of approximately 85% over the current price of $0.54. However, coverage is limited to only one analyst, which implies zero dispersion but simultaneously reflects weak institutional consensus and increased risk due to the limited analytical perspectives.

As of 2026-08-19
Revisions momentum · 30d
⁦0.0%⁩
Average rating
★ 3.00
Hold
Analyst coverage
2
Buy conviction
0%
Target dispersion
0%
Analyst ratings over time2 analysts rating
2
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months4.00 → 3.00
Recent analyst moves
  • = Reiterate2026-08-18
    H.C. Wainwright
    Neutral
  • ⬇ Downgrade2026-06-18
    H.C. Wainwright
    BuyNegative
  • ⬇ Downgrade2026-06-15
    Citigroup
    Neutral
Premium content
Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
MetricValuePosition within sectorVerdict
  • P/E (TTM)
    0.06x
    3.68x44.95x
    Very cheap
  • Forward P/E
    —
    —
  • EV / EBITDA
    —
    —
  • FCF Yield
    -275.8%
    -145.2%7.8%
    Weak
  • Revenue Growth YoY
    —
    —
  • EPS Growth YoY
    83.5%
    -159.3%129.8%
    Strong
  • Gross Margin
    —
    —
  • ROIC
    —
    —
  • Net Debt / EBITDA
    —
    —
  • Dividend Yield
    —
    —
  • Payout Ratio
    —
    —
  • Altman Z-Score
    —
    —
Financial Analysis
|